The Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) Administrative Unit aims to effectively generate and administer the policies, procedures, communications, and funds associated with CEGIR. The CEGIR Administrative Unit will be integral in coordinating decision-making and implementation to achieve the objectives of CEGIR. The CEGIR Administrative Unit will include the CEGIR Director (Principal Investigator), Administrative Director, and the CEGIR Internal CEGIR Steering Committee. The Internal CEGIR Steering Committee has strong patient advocacy group [PAG;e.g. American Partnership for Eosinophilic Disorders (APFED) and Campaign Urging Research for Eosinophilic Diseases (CURED)] and professional medical research group representation [e.g. International Eosinophil Society (lES) and The International Gastrointestinal Eosinophil Researchers (TIGER)]. Specific activities ofthe CEGIR Administrative Unit include but are not limited to the following: 1) generate and administer policies;2) administer and monitor funds;3) ensure proper research conduct by all sites, including patient enrollment and retention;4) review reports from each CEGIR program/component;5) communicate and report to the National Institutes of Health (NIH) and other regulatory bodies;6) disseminate findings, including publications;7) disseminate web-based information as per NIH guidelines and directives;8) foster integration and partnership with PAGs;9) report to the External Advisory Board (EAB) and review their recommendations;and 10) conduct regular teleconferences, webinars, and meetings.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
1U54AI117804-01
Application #
8894260
Study Section
Special Emphasis Panel (ZTR1-CI-8 (01))
Project Start
Project End
Budget Start
2014-08-15
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$228,100
Indirect Cost
$50,212
Name
Cincinnati Children's Hospital Medical Center
Department
Type
DUNS #
071284913
City
Cincinnati
State
OH
Country
United States
Zip Code
45229
Whelan, Kelly A; Muir, Amanda B; Nakagawa, Hiroshi (2018) Esophageal 3D Culture Systems as Modeling Tools in Esophageal Epithelial Pathobiology and Personalized Medicine. Cell Mol Gastroenterol Hepatol 5:461-478
Zevit, Noam; Furuta, Glenn T (2018) Eosinophilic Gastroenteritis and Colitis: Not Yet Ready for the Big Leagues. J Pediatr Gastroenterol Nutr 67:1-2
Durrani, Sandy R; Mukkada, Vincent A; Guilbert, Theresa W (2018) Eosinophilic Esophagitis: an Important Comorbid Condition of Asthma? Clin Rev Allergy Immunol 55:56-64
Rochman, Mark; Azouz, Nurit P; Rothenberg, Marc E (2018) Epithelial origin of eosinophilic esophagitis. J Allergy Clin Immunol 142:10-23
Philpott, Hamish; Dellon, Evan (2018) Histologic improvement after 6 weeks of dietary elimination for eosinophilic esophagitis may be insufficient to determine efficacy. Asia Pac Allergy 8:e20
Fahey, Lisa M; Chandramouleeswaran, Prasanna M; Guan, Shaobo et al. (2018) Food allergen triggers are increased in children with the TSLP risk allele and eosinophilic esophagitis. Clin Transl Gastroenterol 9:139
Wechsler, Joshua B; Bolton, Scott M; Amsden, Katie et al. (2018) Eosinophilic Esophagitis Reference Score Accurately Identifies Disease Activity and Treatment Effects in Children. Clin Gastroenterol Hepatol 16:1056-1063
Pesek, Robert D; Gupta, Sandeep K (2018) Emerging drugs for eosinophilic esophagitis. Expert Opin Emerg Drugs 23:173-183
Spergel, Jonathan M; Aceves, Seema S; Kliewer, Kara et al. (2018) New developments in patients with eosinophilic gastrointestinal diseases presented at the CEGIR/TIGERS Symposium at the 2018 American Academy of Allergy, Asthma & Immunology Meeting. J Allergy Clin Immunol 142:48-53
Mark, Jacob; Fernando, Shahan D; Masterson, Joanne C et al. (2018) Clinical Implications of Pediatric Colonic Eosinophilia. J Pediatr Gastroenterol Nutr 66:760-766

Showing the most recent 10 out of 103 publications